CD274 and neoplasm: Currently, predictive biomarkers for immunotherapy mainly include programmed death-ligand 1 (PD-L1), microsatellite instability/defective mismatch repair (MSI/dMMR), and tumor mutational burden, but often ignore the problem of “poor soil” (10).